Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.

[1]  M. Reni,et al.  Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. , 2017, Cancer treatment reviews.

[2]  K. Flaherty,et al.  Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. , 2017 .

[3]  A. Bullock,et al.  Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). , 2017 .

[4]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial , 2017, OncoTargets and therapy.

[5]  M. Reni,et al.  B01*A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back , 2016 .

[6]  M. Reni,et al.  Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma , 2016, British Journal of Cancer.

[7]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[8]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[10]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[11]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[12]  T. Conroy,et al.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Kubota,et al.  Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism , 2004, Cancer science.

[14]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S K Carter,et al.  Calibrated phase II clinical trials in oncology. , 1986, Statistics in medicine.

[16]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .

[17]  M. Reni,et al.  A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) , 2011, Cancer Chemotherapy and Pharmacology.

[18]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.